Kidney considerations in pediatric obesity

A Sawyer, E Zeitler, H Trachtman, P Bjornstad - Current Obesity Reports, 2023 - Springer
Abstract Purpose of Review Chronic kidney disease (CKD) is a common condition and a
major cause of morbidity and mortality in adults, but children and adolescents are also at risk …

The pillars for renal disease treatment in patients with type 2 diabetes

J Kearney, L Gnudi - Pharmaceutics, 2023 - mdpi.com
The diabetes epidemic and the increasing number of patients with diabetic chronic vascular
complications poses a significant challenge to health care providers. Diabetic kidney …

An Imbalance of Pathophysiologic Factors in Late Postprandial Hypoglycemia Post Bariatric Surgery: A Narrative Review

M Alsayed Hasan, S Schwartz, V McKenna, R Ing - Obesity Surgery, 2023 - Springer
With a rise in obesity and more patients opting for bariatric surgery, it becomes crucial to
understand associated complications like postprandial hypoglycemia (PPH). After bariatric …

[HTML][HTML] GLP-1 receptor agonists, SGLT-2 inhibitors, and obstructive sleep apnoea: can new allies face an old enemy?

GS Papaetis - Archives of Medical sciences. Atherosclerotic …, 2023 - ncbi.nlm.nih.gov
Obstructive sleep apnoea (OSA) is the most common form of abnormal sleep pattern (ASP).
It is characterized by narrowing of the upper airways (complete or partial) during sleep …

Novel Approaches in Chronic Renal Failure without Renal Replacement Therapy: A Review

SL Martínez-Hernández, MH Muñoz-Ortega… - Biomedicines, 2023 - mdpi.com
Chronic kidney disease (CKD) is characterized by renal parenchymal damage leading to a
reduction in the glomerular filtration rate. The inflammatory response plays a pivotal role in …

Effect of once-weekly dulaglutide on renal function in patients with chronic kidney disease

S Kim, JN An, YR Song, SG Kim, HS Lee, AJ Cho… - Plos one, 2022 - journals.plos.org
Background Dulaglutide is associated with improved cardiovascular and kidney outcomes
and can be a good therapeutic option for patients with type 2 diabetes with chronic kidney …

[HTML][HTML] Obesity-related hypertension and chronic kidney disease: from evaluation to management

MH Jung, SH Ihm - Kidney Research and Clinical Practice, 2023 - ncbi.nlm.nih.gov
With the recent obesity pandemic, obesity-related hypertension and its complications (eg,
heart failure, coronary disease, and chronic kidney disease [CKD]) are gaining attention in …

Incretin and glucagon receptor polypharmacology in chronic kidney disease

BE McFarlin, KL Duffin… - American Journal of …, 2024 - journals.physiology.org
Chronic kidney disease is a debilitating condition associated with significant morbidity and
mortality. In recent years, the kidney effects of incretin-based therapies, particularly glucagon …

Efficacy and safety of tirzepatide, GLP‐1 receptor agonists, and other weight loss drugs in overweight and obesity: a network meta‐analysis

XH Pan, B Tan, YH Chin, ECZ Lee, G Kong, B Chong… - …, 2024 - Wiley Online Library
Objective This network meta‐analysis evaluates the efficacy and safety of tirzepatide
compared to glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and other weight loss …

Finerenone: From the Mechanism of Action to Clinical Use in Kidney Disease

N Piko, S Bevc, R Hojs, R Ekart - Pharmaceuticals, 2024 - mdpi.com
Diabetic kidney disease is a frequent microvascular complication of diabetes and is currently
the leading cause of chronic kidney disease and end-stage kidney disease worldwide …